Contact us Demo our platform

Case Study

Monitoring Therapeutics for Rare Diseases with Metabolomics

Metabolomics presents a unique opportunity to develop a complete understanding of the metabolic imbalance before therapy and to appreciate a drug’s impact on metabolic pathways.

Metabolon’s untargeted metabolomics technology can be used to predict the effectiveness of a drug and monitor disease development. Therefore, metabolomics offers researchers an effective route to address some of the issues associated with discovering and monitoring therapeutics.

Talk With An Expert About Your Project

The Global Discovery Panel can be used to predict the effectiveness of a drug and monitor disease development. Therefore, metabolomics offers researchers an effective route to address some of the issues associated with discovering and monitoring therapeutics.

Talk With An Expert About Your Project
rare disease therapeutics

The Challenge: Combatting Rare Genetic Diseases

Researchers identified a new autosomal dominant genetic syndrome—Bachmann-Bupp Syndrome (BABS)—in a 3-year-old patient. BABS is an ultra-rare neurometabolic disorder associated with several clinical features, including global developmental delay and alopecia. It is caused by de novo mutations in the ornithine decarboxylase 1 (ODC1) gene that ultimately lead to its enhanced activity.1 ODC1 controls polyamine biosynthesis, which orchestrates fundamental physiological and cell developmental processes.

Eflornithine is an ornithine decarboxylase (ODC) inhibitor that has been previously approved to treat African sleeping sickness and has shown promise in clinical trials for pediatric neuroblastoma.2 To test eflornithine against the patient’s specific mutation, the researchers treated some of the patient’s skin cells with eflornithine and found that it reduced ODC activity in vitro. This suggested that repurposing eflornithine could therapeutically suppress the high ODC activity in the BABS patient.

Metabolon Insight: Evaluating Eflornithine as a Treatment for BABS

Metabolon’s untargeted metabolomics technology was used to analyze plasma samples. This allowed the research group to evaluate the patient’s metabolomic profile before and after treatment to assess eflornithine’s efficiency.

The Solution: Eflornithine Normalizes Polyamine-Related Metabolites

The research group collaborated with Metabolon to perform metabolomic analysis of plasma samples from the patient prior to and after initiating treatment with eflornithine. The metabolite levels of a reference cohort of 866 pediatric patients were converted to Z-scores and compared to the patient’s metabolomic profile. Out of the 915 metabolites identified in the patient before treatment, a total of 16 metabolites had values above the 97.5th percentile and 38 metabolites below the 2.5th percentile, with a robust difference in polyamine-related metabolites without any marked disruption of any other metabolic pathways on treatment.

Eflornithine treatment also stabilized the patient’s polyamine levels without disrupting other pathways. The initial elevation of N-acetylputrescine and acisoga, which were above the 97.5th percentile, decreased right after initiating therapy and remained reduced throughout the treatment, indicating that eflornithine treatment normalized the polyamine pathway. In addition to reducing ODC activity, eflornithine treatment also led to significant hair growth and remarkable improvement in neurological symptoms after 6 months of eflornithine treatment. The patient gained better posture and the capacity to feed herself. Post-treatment MRIs revealed normalization of her cerebral white matter, which is a sign that the drug might be spurring neurological improvements.

The Outcome: Eflornithine Can be Repurposed to Treat BABS

Global metabolomics offers a unique opportunity to develop a more complete understanding of the metabolic imbalance before therapy, to understand the drug’s impact on interconnected metabolic pathways, and to identify potential adverse effects. These findings may lead to earlier initiation of therapy in future BABS patients, thereby perhaps avoiding some of the neurological delays that have come to characterize the patient’s disease in the study. This work demonstrates that Metabolon’s untargeted metabolomics technology can be used to predict the effectiveness of a drug and monitor disease development. Therefore, metabolomics offers researchers an effective route to address some of the issues associated with drug therapeutics discovery and monitoring.

References

1. Rajasekaran S, Bupp CP, Leimanis-Laurens M, et al. Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease. Elife. 2021;10:e67097. Published 2021 Jul 20. doi:10.7554/eLife.67097

2. Bupp CP, Schultz CR, Uhl KL, Rajasekaran S, Bachmann AS. Novel de novo pathogenic variant in the ODC1 gene in a girl with developmental delay, alopecia, and dysmorphic features. Am J Med Genet A. 12 2018;176(12):2548-2553. doi:10.1002/ajmg.a.40523

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.